| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $30,000,000 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Flynn James E | * Director by Deputization | 1 | $30M | 0 | $0 | $30M |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Over the last 12 months, insiders at Larimar Therapeutics, Inc. have bought $30M and sold $0 worth of Larimar Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Larimar Therapeutics, Inc. have bought $27.7M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Flynn James E (* Director by Deputization) — $30M.
The last purchase of 9,375,000 shares for transaction amount of $30M was made by Flynn James E (* Director by Deputization) on 2025‑07‑31.
| 2025-07-31 | Flynn James E | * Director by Deputization | 9.38M 13.5418% | $3.20 | $30M | +7.51% | ||
| 2024-02-16 | Flynn James E | * Director by Deputization | 4.29M 6.6831% | $8.74 | $37.5M | -41.94% | ||
| 2024-02-16 | Hamilton Thomas Edward | director | 57,208 0.0891% | $8.74 | $499,998 | -41.94% | ||
| 2024-02-14 | THOMAS FRANK E | director | 2,000 0.0064% | $11.00 | $22,000 | -37.88% | ||
| 2023-12-07 | Shankar Gopi | Chief Development Officer | 5,000 0.0119% | $3.73 | $18,662 | +105.22% | ||
| 2023-05-17 | BEN-MAIMON CAROLE | President and CEO | 5,000 0.0114% | $3.71 | $18,525 | +8.67% | ||
| 2023-05-17 | Celano Michael | Chief Financial Officer | 5,000 0.0115% | $3.73 | $18,632 | +8.67% | ||
| 2023-05-17 | Truitt Joseph | director | 2,750 0.0063% | $3.73 | $10,258 | +8.67% | ||
| 2022-09-16 | Flynn James E | 11.11M 49.2054% | $3.15 | $35M | +21.72% | |||
| 2022-09-16 | Hamilton Thomas Edward | director | 317,460 1.4059% | $3.15 | $999,999 | +21.72% | ||
| 2022-09-16 | BEN-MAIMON CAROLE | President and CEO | 31,746 0.1406% | $3.15 | $100,000 | +21.72% | ||
| 2022-09-16 | Celano Michael | Chief Financial Officer | 31,746 0.1406% | $3.15 | $100,000 | +21.72% | ||
| 2021-06-30 | Flynn James E | 685,710 3.341% | $8.75 | $6M | -2.39% | |||
| 2021-06-30 | Hamilton Thomas Edward | director | 56,710 0.2763% | $8.75 | $496,213 | -2.39% | ||
| 2018-06-28 | Sale | Hughes Thomas E. | See Remarks | 32,000 0.1034% | $10.00 | $320,000 | -47.50% | |
| 2018-03-07 | Sale | Hughes Thomas E. | See Remarks | 5,000 0.0194% | $10.00 | $50,000 | -8.25% | |
| 2017-10-13 | Heller Frances K | director | 20,000 0.0343% | $1.95 | $38,988 | +75.12% | ||
| 2017-07-11 | KIM DENNIS D | Chief Medical Officer | 20,000 0.037% | $1.70 | $33,900 | +63.77% | ||
| 2017-05-11 | KIM DENNIS D | Chief Medical Officer | 19,600 0.0729% | $4.40 | $86,240 | -12.41% | ||
| 2017-05-10 | KIM DENNIS D | Chief Medical Officer | 400 0.0014% | $4.40 | $1,760 | -15.92% |
| Flynn James E | * Director by Deputization | 9538945 11.1449% | $28.9M | 8 | 1 | <0.0001% |
| Hamilton Thomas Edward | director | 564798 0.6599% | $1.71M | 3 | 0 | <0.0001% |
| BEN-MAIMON CAROLE | President and CEO | 266829 0.3118% | $808,491.87 | 2 | 0 | +15.2% |
| STARR KEVIN P | director | 210371 0.2458% | $637,424.13 | 0 | 1 | |
| Hughes Thomas E. | See Remarks | 125247 0.1463% | $379,498.41 | 2 | 4 | +20.01% |
| Celano Michael | Chief Financial Officer | 112746 0.1317% | $341,620.38 | 2 | 0 | +15.2% |
| Goldberg Avi Y. | director | 53734 0.0628% | $162,814.02 | 0 | 3 | |
| Heller Frances K | director | 47961 0.056% | $145,321.83 | 4 | 0 | +29.04% |
| KIM DENNIS D | Chief Medical Officer | 21443 0.0251% | $64,972.29 | 3 | 3 | +11.81% |
| Allen Patricia L | Chief Financial Officer | 19793 0.0231% | $59,972.79 | 2 | 0 | +14.98% |
| Shankar Gopi | Chief Development Officer | 5000 0.0058% | $15,150.00 | 1 | 0 | +105.22% |
| Truitt Joseph | director | 2750 0.0032% | $8,332.50 | 1 | 0 | +8.67% |
| THOMAS FRANK E | director | 2000 0.0023% | $6,060.00 | 1 | 0 | <0.0001% |
| Secor Alicia | Chief Commercial Officer | 0 0% | $0 | 1 | 1 | +21.04% |
$8,708,580 | 93 | -5.38% | $236.31M | |
$69,151,774 | 71 | 24.96% | $303.01M | |
$1,323,997 | 34 | 0.21% | $272.62M | |
Larimar Therapeutics, Inc. (LRMR) | $79,019,806 | 27 | 7.24% | $259.34M |
$22,017,898 | 24 | 39.19% | $239.56M | |
$3,668,031 | 23 | 2.05% | $273.12M | |
$1,842,003 | 22 | -0.74% | $266.93M | |
$6,915,275 | 21 | -32.61% | $252.76M | |
$22,365,077 | 19 | -27.47% | $309.08M | |
$110,580 | 16 | 14.52% | $257.1M | |
$4,701,608 | 14 | -4.34% | $240.06M | |
$13,043,783 | 8 | 732.82% | $284.95M | |
$91,549,696 | 8 | -6.55% | $296.72M | |
$1,346,998 | 7 | 25.06% | $271.79M | |
$272,982 | 6 | -28.53% | $225.71M | |
$8,286,963 | 6 | 3.09% | $239.13M | |
$37,067 | 3 | -89.81% | $253.31M | |
$1,516,110 | 3 | 8.05% | $236.64M | |
$2,720,023 | 3 | -11.76% | $269.21M |
| Increased Positions | 71 | +51.08% | 25M | +36.21% |
| Decreased Positions | 58 | -41.73% | 6M | -8.68% |
| New Positions | 26 | New | 8M | New |
| Sold Out Positions | 14 | Sold Out | 786,975 | Sold Out |
| Total Postitions | 152 | +9.35% | 86M | +27.53% |
| Deerfield Management Company, L.P. | $106,206.00 | 35.59% | 30.61M | +9M | +44.16% | 2025-09-30 |
| Ra Capital Management, L.P. | $20,977.00 | 7.03% | 6.05M | 0 | 0% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $20,310.00 | 6.81% | 5.85M | +925,000 | +18.77% | 2025-09-30 |
| Millennium Management Llc | $16,992.00 | 5.69% | 4.9M | +1M | +33.97% | 2025-09-30 |
| Opaleye Management Inc. | $12,911.00 | 4.33% | 3.72M | -389,133 | -9.47% | 2025-09-30 |
| Blackrock, Inc. | $11,587.00 | 3.88% | 3.34M | +299,212 | +9.84% | 2025-09-30 |
| Rtw Investments, Lp | $10,844.00 | 3.63% | 3.13M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $10,715.00 | 3.59% | 3.09M | +945,809 | +44.16% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $6,593.00 | 2.21% | 1.9M | +2M | New | 2025-09-30 |
| Alyeska Investment Group, L.P. | $6,548.00 | 2.19% | 1.89M | -188,713 | -9.09% | 2025-09-30 |